Dr. Salma Jabbour’s NCI Research Specialist (Clinician Scientist) Award (R50)

Salma Jabbour 博士荣获 NCI 研究专家（临床科学家）奖 (R50)

• 批准号: 10563885
• 负责人: Salma Jabbour
• 金额: $ 19.62万
• 依托单位: RUTGERS BIOMEDICAL AND HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-01 至 2028-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10563885
• 关键词: American College of Radiology Imaging Network; Award; Cancer Institute of New Jersey; Cancer Therapy Evaluation Program; Caring; Clinical; Clinical Trials; Clinical Trials Network; Collaborations; Combined Modality Therapy; Complex; Development; Early Therapeutic-Clinical Trials Network; Eastern Cooperative Oncology Group; Funding; Grant; Human; Institution; Interest Group; Leadership; Malignant Neoplasms; Mentors; Mentorship; Oncology; Patient Care; Patients; Physicians; Play; Protocols documentation; Radiation; Research; Research Personnel; Role; Scientist; Seasons; Services; Specialist; Time; Work; cancer care; cancer clinical trial; career; design; gastrointestinal; innovation; novel; programs

ABSTRACT Oncology clinical trials are increasingly complex in their design, management, and oversight, and clinical trials continue as the cornerstone to transform cancer care for patients. These multifaceted trials require significant partnership from the institution and investigators to provide support and effort as well as multifaceted teams to conduct and execute these trials seamlessly and effectively. Furthermore, the dissemination of clinical trial findings in a timely and efficient manner requires the continued support from the clinical trials teams, biostatisticians, and co-investigators in terms of time and effort. Dr. Jabbour is a seasoned research specialist, physician scientist, and clinician scientist having a proven track record of diligence and innovation as well as purpose to design, carry out, and complete clinical trials. Her long-standing commitment to clinical trials is paramount as she is a leader at the Rutgers Cancer Institute of New Jersey in mentoring and supporting other clinical trialists, having overseen the Human Research Oversight Committee (HROC/DSMB) and currently overseeing the Scientific Review Board, and she plays integral role in the oversight of clinical trials through a variety of committees both at Rutgers Cancer Institute and nationally. At the national level, Dr. Jabbour is the contact PI for the Rutgers Cancer Institute ETCTN/CTEP grant funding, is a long-standing Co-Chair for the NCI Radiation Research Program Gastrointestinal Interest Group, and is actively involved in a variety of NCI Cooperative Group Committees and Protocols including the ECOG-ACRIN and NRG Oncology Cooperative Groups. Dr. Jabbour is a continued leader and pioneer as a clinician scientist and actively studies the use of novel agents in combination with radiation in ground-breaking clinical trials. Dr. Jabbour will continue her exemplary efforts and work under the auspices of this R50 Mechanism and will continue to revolutionize the care for oncology patients through her state-of-the-art concepts and collaborations through the NCI national cooperative groups.

抽象的 肿瘤临床试验的设计、管理和监督以及临床试验变得越来越复杂 继续作为改变癌症患者护理的基石。这些多方面的试验需要大量 机构和研究人员的合作伙伴关系提供支持和努力，以及多方面的团队 无缝有效地进行和执行这些试验。此外，临床试验的传播 及时有效的发现需要临床试验团队的持续支持， 生物统计学家和共同研究人员的时间和精力。 Jabbour 博士是一位经验丰富的研究专家， 具有良好的勤奋和创新记录以及良好的医师科学家和临床科学家 目的是设计、实施和完成临床试验。她对临床试验的长期承诺是 至关重要的是，她是新泽西州罗格斯癌症研究所的领导者，负责指导和支持其他人 临床试验专家，曾监督人类研究监督委员会 (HROC/DSMB)，目前 监督科学审查委员会，她通过一个机构在临床试验的监督中发挥着不可或缺的作用 罗格斯癌症研究所和全国范围内的各种委员会。在国家层面，贾布尔博士是 罗格斯癌症研究所 ETCTN/CTEP 赠款资金的联系人 PI，是 NCI 的长期联合主席 放射研究计划胃肠兴趣小组，并积极参与各种NCI 合作小组委员会和协议，包括 ECOG-ACRIN 和 NRG 肿瘤学合作组织 团体。 Jabbour 博士是临床科学家的持续领导者和先驱，并积极研究使用 在突破性的临床试验中与放射治疗相结合的新型药物。贾布尔博士将继续她的工作 在 R50 机制的支持下做出了堪称典范的努力和工作，并将继续彻底改变 通过她最先进的理念和与 NCI 国家合作，为肿瘤患者提供护理 合作团体。